

# Looking for research funding?



## Hello there!

This document summarizes funding opportunities for health-related research including Dutch, international and philanthropic grants. To support you with applications for funding, I work together with a whole team of research funding advisors at TUD Innovation and Impact Centre as well as colleagues at TUD University Fund (see next page).

If you are interested in applying to opportunities mentioned here or if you are already working on a research proposal, [contact me!](#) We can discuss your ideas, consortium and call requirements.

Together we can make sure your proposal aligns well with call objectives.

Looking forward to hearing from you!

Jaga Schreiber

**Jaga Schreiber**  
**Health Funding Advisor**  
TU Delft Innovation and Impact Centre  
M +31 (0) 6 28362580  
[j.k.schreiber@tudelft.nl](mailto:j.k.schreiber@tudelft.nl)

# Tech for Health

Better healthcare thanks to Delft technology

## Approaching philanthropic Foundations

In search of funding for your research through philanthropic foundations? Do not hesitate to contact me. Working at [Delft University Fund](#), I am responsible for attracting funding from foundations and family offices. In the Netherlands, we work successfully with several foundations and are currently piloting the international foundation market. My experience lies in developing relationships within this market to complement calls for proposals or to create opportunities for unsolicited proposals.

In 2021, we especially focus on research about *health & care* through the alumni campaign [Tech for Health](#). So if your research requires complementary funding from the 4<sup>th</sup> income stream, or if you have any ideas and questions related to funding in this market, please, do not hesitate to contact me.

Ps. if your research is not health-related, you are of course still very welcome to contact me with any questions or ideas you may have.

 TU Delft

University Fund



**Eelco Akkerboom**

**Account Manager Foundations**

M +31 (0)6 39267053

[E.A.Akkerboom@tudelft.nl](mailto:E.A.Akkerboom@tudelft.nl)

# Looking for research funding?



## Content of the newsletter



Dutch funding	International funding	Others/foundations
<a href="#">Open Technology Programme 2022</a>	<a href="#">Horizon Europe main work programs</a>	<a href="#">HFSP Research Grant Program - HFSP</a>
<a href="#">Open Competition Domain Science - M</a>	<a href="#">Horizon Europe Cluster 1 Health - 10 call examples</a>	<a href="#">Programma Onderzoek &amp; Implementatie and Exploratie - KWF</a>
<a href="#">Cell-Based Technologies Flanders – Netherlands LSH / RVO</a>	<a href="#">Horizon Europe Cluster 1: Data and Artificial Intelligence and health – 4 calls</a>	<a href="#">Alzheimer Nederland Call Biomedical Research</a>
<a href="#">Dutch Research Agenda - Research along Routes by Consortia 2022 (NWA-ORC 2022)</a>	<a href="#">Horizon Europe Cluster 4 Digital, Industry and Space Bio-materials / biomedical application of materials – 3 calls</a>	<a href="#">De Stichting tot Steun VCVGZ geestelijke gezondheidszorg</a>
<a href="#">NWO KIC Access to care in the living environment</a>	<a href="#">Horizon Europe Cluster 6 Food, Bioeconomy, Natural Resources, Agriculture and Environment – 2 call examples</a>	
<a href="#">Coming soon: NRF-NWO Integrating Health Approaches and the Water-Energy-Food-Nexus</a>	<a href="#">EIC Pathfinder Challenge 2022: Cardiogenomics, Healthcare Continuum technologies</a>	



# Open Technology Programme 2022

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x	x	x	x

**Purpose:** Researchers from all disciplines can submit proposals for application-oriented technical-scientific research via the OTP. The goal of this programme is **to realise knowledge transfer between technical sciences and users**. For companies and partners it offers a low-threshold way to connect with application-oriented research. This can be done by making a financial or material contribution. An application must contain a substantial proportion of research activities. Research proposals are examined for scientific quality and from the perspective of utilisation. Both criteria are given equal weight in the decision-making process. New knowledge and insights from scientific research can make an important contribution to solutions for current and future societal issues.

**Who can apply:** Full, associate and assistant professors and researchers with a comparable position or a tenure trackers

**Consortium:** Main applicant, Co-applicants and users. Co-applicants must play an active role in conducting the project. The (sub-)project leaders and beneficiary or beneficiaries are jointly responsible for implementation of the entire project. Users contribute to the project in kind or in cash (at least four users and at least two non-academic parties)

**Budget:** € 850,000 (including VAT). For projects of an investment nature (> € 150,000 in investments), the maximum AES contribution is M€ 1, including VAT. Grant ceiling for call 2022 (from Jan to 15 December 2022) is € 21,000,000.

**Co-funding requirement:** If the total project costs exceed € 600,000, a contribution to the project costs (co-funding) by users is required, namely 25% of the sum in excess of € 600,000. Co-funding: financial and/or in-kind contribution(s) (in kind = capitalised personnel and/or material contributions from users)

**Deadline:** from 1.01.2022-15.12.2022, continuously

**Evaluation criteria:** Scientific quality (50%) and Knowledge utilisation (50%)

**Information:** [NWO OTP website](#), [call for proposals](#)





# Open Competition Domain Science - M

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x	x	x	x

**Purpose:** ENW-M grants are intended for realising curiosity-driven scientific research of high quality. The ENWM grant offers researchers the opportunity to elaborate original, innovative, risky ideas and to realise scientific innovations that can form the basis for the research themes of the future. There are three categories of ENW-M grants: ENW-M-1 (1 scientific position), ENW-M-2 (2 scientific positions in collaboration) and ENW-M-invest (investments) that are assessed in competition with each other. For this Call for proposals, your application must fit in the NWO Domain Science: fields of earth sciences, astronomy, chemistry, computer science, life sciences, physics and mathematics.

**Who can apply:** Full, associate and assistant professors and researchers with a comparable position if they have a tenured position (and therefore a paid position for an indefinite period) or a tenure track agreement;

ENW-M-1 and ENW-M-invest have a **single main** applicant and no co-applicants.

ENW-M-2 has a **single main applicant** and a **single co-applicant** who work together and whose expertise is complementary. Main applicant and co-applicant may be employed by the same organisation, as long as their expertise is complementary.

A main applicant or co-applicant may only submit an ENW-M proposal for substantive consideration **once every 12 months**.

**Budget:** ENW-M-1 grant has a maximum size of € 350,000; ENW-M-2 grant has a maximum size of € 700,000; ENW-M-invest grant has a minimum size of € 150,000 and a maximum size of € 500,000; for the period 6 August 2021 up to and including 31 July 2022 is € 32,000,000.

**Co-funding requirement:** none

**Deadline:** **Continuous;** by July 31, 2022

**Evaluation criteria:** Criterion 1: Scientific quality of the proposal (What), Criterion 2: Scientific and/or societal impact (Why); Criterion 3: Embedding and use of the investment (only for ENW-M-invest)

**Information:** [NWO Science M website](#), [call for proposals](#)



# Cell-Based Technologies Flanders – Netherlands

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

**Purpose:** For this call there is a common interest in promoting bilateral public-private research and development collaboration projects within the scope of Cell-Based Technologies. For instance cell- and **gene therapy, human disease models, tissue engineered products and necessary quality, safety and efficacy standards for personalised medicine and health, where cell-based technologies form an underlying basis.** Where possible, we invite consortia to combine biomedical, technological and data-driven expertise in their applications.

**Who can apply/ Consortium:** at least one independent company from Flanders, one independent company from the Netherlands and one research organisation from the Netherlands. In Flanders, research organisations can participate as subcontractor or research partner of the Flemish company, but not as a direct beneficiary of the subsidy.

**Budget:** LSH (Health~Holland) provides a budget of €1.000.000, with the max. funding per project for the Dutch part of € 350.000. In Flanders, VLAIO has allocated a total budget of ~ € 1.000.000 for this call. The maximum funding (subsidy) per project for the Flemish part is € 350.000. For none of the beneficiaries the requested budget can exceed 70% of the total project budget;

**Co-funding requirement:** LSH grants provide 50% funding for industrial research activities and 25% for experimental development activities; LSH requires minimum 30% contribution of project costs of (for-profit) enterprises in the consortium. This contribution can be in cash and/or in kind, depending on the size of the enterprise. At least 2/3 of the required minimum contribution of a large enterprise must consist of a cash contribution. The contribution of SMEs may be fully in kind.

**Deadline:** Pre-registration (mandatory) by **March 1, 2022**; Submission full project proposal by May 2, 2022

Pre-registration form is on LSH ([link](#)) and/or Netherlands Enterprise Agency ([link](#)) websites. The completed pre-registration form should be submitted to the national EUREKA offices simultaneously **by email** to contact persons at VLAIO ([patricia.menten@vlaio.be](mailto:patricia.menten@vlaio.be)) and Netherlands Enterprise Agency ([teamiris@rvo.nl](mailto:teamiris@rvo.nl)), with copy to all partners of the consortium.

Matchmaking platform is [HERE](#)

**Evaluation criteria:** Impact (e.g. value creation, competitive advantages), Excellence (degree of innovation, challenging scientifically), Quality and efficiency of implementations (including quality of consortium)

**Information:** LSH ([link](#)) and/or Netherlands Enterprise Agency ([link](#)) websites





# Dutch Research Agenda - Research along Routes by Consortia 2022 (NWA-ORC 2022)

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x	x	x	x

**Purpose:** The aim of the NWA-ORC 2022 call for proposals is to encourage research that is set up and carried out by interdisciplinary consortia that include representatives from the full breadth of the knowledge chain as well as relevant societal (public and/or private) partners, including citizens. The research will address so called wicked problems, focused on the portfolio of [25 routes and the 140 corresponding cluster questions in the NWA](#). The starting point for this is the Portfolio for Research and Innovation. The application process for this annual funding round of the Dutch Research Agenda (NWA) starts with the **submission of initiatives**. **NWA seeks to connect with society:** The aim of NWA research is to **deploy knowledge to make a positive, structural contribution to tomorrow's society** by building bridges today and jointly ensure scientific breakthroughs and societal impact. NWO brings together research and civil society organisations and funds thematic research, network formation and science communication.

**Planning NWA-ORC 2022** The application process has three phases:

The **registration of an initiative** closes on 1 February 2022. / In March 2022, **matchmaking meetings** will take place.

The submission of a **pre-proposal closes on 9 June 2022**. Mid-October, applicants will receive an advice about full proposal. The submission of the full proposal closes on 24 January 2023.

**Who can apply:** Proposals should be submitted by a consortium in which the various types of research in the knowledge chain (fundamental, applied and practice-oriented) are represented. There are four categories of participant within a consortium: Main applicant; Co-applicant(s); Co-funder(s); Cooperating partner(s) (optional).

**Budget:** In this round, proposals with a project duration of 4-8 years can be submitted in the following budget ranges: 500,000 – ≤ 2,000,000 euros; > 2,000,000 – ≤ 5,000,000 euros; > 5,000,000 – ≤ 10,000,000 euros.

**More information:** [NWO NWA-ORC 2022](#); [call for proposals \(in Dutch\)](#)

14/12/2021





# NWO KIC Access to care in the living environment

(Mission I: Lifestyle and living environment Mission II: Care in the living environment)

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x	x	x	x

**Purpose:** The aim of this call is to contribute to the health and self-reliance of citizens. To facilitate and maintain this, research needs to be carried out aimed at the further development, application and effective use of technology in the own living environment that contributes to a healthy lifestyle and to transferring care and support to the own living environment. This call focuses on Mission I: Lifestyle and living environment and Mission II: Care in the living environment. For the call to be successful, funding will be awarded to interdisciplinary public-private consortia who have incorporated at least the following elements in their project:

- Research into conscious and unconscious decision support and/or innovations for individuals and their direct environment that contribute to a healthy lifestyle and living environment as well as the transfer of care and support to the own living environment.
- Further development, application and effective use of technology; containing one or more medical devices as defined in the Medical Device Regulation.
- Development of integrated system solutions via an interdisciplinary and integral research approach with all relevant parties: citizens, companies, government bodies and researchers ('quadruple helix').
- Further development of proven effective elements and sustainable innovative preventative interventions and the assessment of these in field labs (for example, GROZzerdammen)

**Who can apply:** Proposals should be submitted by a consortium in which the various types of research in the knowledge chain (fundamental, applied and practice-oriented) are represented. There are four categories of participant within a consortium: Main applicant; Co-applicant(s); Co-funder(s); Cooperating partner(s) (optional). Full, associate and assistant professors, lectors, and other researchers with a comparable position\* may act as main or co-applicant.

**Budget:** between € 850.000 - € 2550.000; NWO finances maximally 85% of the total project budget;

**Co-funding requirement:** The co-funders jointly contribute a net minimum amount of 15% of the total budget for the proposal.

**Deadline:** pre-proposals is March 24, 2022; full proposals is September 22, 2022

**More information:** [NWO KIC call](#); [call for proposals](#)





# Coming soon: NRF-NWO call on Integrating Health Approaches and the Water-Energy-Food-Nexus

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
			X

Coming soon: NRF-NWO call on Integrating Health Approaches and the Water-Energy-Food-Nexus

## Coming soon: NRF-NWO call on Integrating Health Approaches and the Water-Energy-Food-Nexus

18 October 2021

The National Research Foundation (NRF) of South Africa and NWO are going to publish a third call on the Water-Energy-Food-Nexus, this time with a focus on integrating health approaches. The call will be launched in November 2021. The deadline for preliminary proposals is expected on 1st March 2022.

### Characteristics

### Research programme

[South Africa](#) | [Merian Fund](#)



### Thematic focus: [integrating health approaches and the WEF nexus](#)

For the third call, the focus will be on integrating health approaches and the WEF nexus. The present pandemic gives reason to include public health as a specific field of attention within the WEF nexus research area. What can we learn from the immediate effects of COVID-19 to make WEF nexus transformations more resilient and robust to risks and crises? And the other way around: can we develop and apply WEF nexus-based transformative approaches to better support pandemic response and preparedness strategies? Expected timeline and budget (not yet definitive)

- November 2021 Call launched (**not yet**)
- 18 January 2022 Deadline research initiatives (not mandatory) –for matchmaking purposes
- 1 March 2022 Deadline pre-proposals
- 29 September 2022 Deadline full proposals

[Matchmaking Cooperation South Africa – the Netherlands: Integrating Health Approaches and WEF-Nexus](#)




# Horizon Europe 2021-2027

Horizon Europe is the EU’s research and innovation framework program running from 2021-2027. Here you will find links to the most important work programs:

Pillar 1:  
[European Research Council \(ERC\) 2022](#)  
[Marie Skłodowska-Curie Actions](#)

Pillar 2:  
[Health](#)  
[Digital, Industry and Space](#)  
[Food, Bioeconomy, Natural Resources, Agriculture and Environment](#)

Pillar 3:  
[European Innovation Council](#)



# Horizon Europe Cluster 1 Health

## Examples of health-calls

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x	x	x	x

Cluster 1 Health	total budget (no. of projects) mln Euro	Type	deadline	stage
<a href="#">HORIZON-HLTH-2022-CARE-08-04 Better financing models for health systems</a>	30(5)	RIA	21.04.2022	1-Stage
<a href="#">HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage Boosting mental Health in Europe in times of change</a>	50(7)	RIA	01.02.2022	2-Stage
<a href="#">HORIZON-HLTH-2022-DISEASE-07-03 Non-communicable diseases risk reduction in adolescence and youth</a>	25(8)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-IND-13-01 Enhancing cybersecurity of connected medical devices</a>	20(6)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-ENVHLTH-04-01 Methods for assessing health-related costs to environmental stressors</a>	20(5)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-STAYHLTH-02-01 Personalised blueprint of chronic inflammation in health-to-disease transition</a>	50(7)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs</a>	60(10)	RIA	01.02.2022	2-stage
<a href="#">HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines</a>	40(5)	RIA	01.02.2022	2-stage
<a href="#">HORIZON-HLTH-2022-IND-13-03 New pricing and payment models for cost-effective and affordable health innovations</a>	15(3)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-STAYHLTH-01-05-two-stage Prevention of obesity throughout the life course</a>	60(6)	RIA	01.02.2022	2-stage
<a href="#">HORIZON-HLTH-2022-DISEASE-06-04-two-stage Development of new effective therapies for rare diseases</a>	60(8)	RIA	01.02.2022	2-stage

Neuro	Cardio	Onco	Other
x	x	x	x

## Horizon Europe Cluster 1: Data and Artificial Intelligence and health

Cluster 1 Health	Total budget (no. of projects) mln Euro	type	deadline	stage
<a href="#">HORIZON-HLTH-2022-STAYHLTH-01-04-two-stage Trustworthy AI tools to predict the risk of chronic non-communicable diseases and/or their progression</a>	60(10)	RIA	01.02.2022	2-Stage
<a href="#">HORIZON-HLTH-2022-IND-13-02 Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation</a>	30(7)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-TOOL-11-02 New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment</a>	35(5)	RIA	21.04.2022	1-stage
<a href="#">HORIZON-HLTH-2022-TOOL-12-01-two-stage Computational models for new patient stratification strategies</a>	60	RIA	01.02.2022	Two Stages

# Horizon Europe Cluster 1 Health

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
			X

## Methods for assessing health-related costs of environmental stressors

TOPIC ID: HORIZON-HLTH-2022-ENVHLTH-04-01

Deadline: **21 April 2022**

Budget: 4mln (20 mln in total, 5 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

**Expected Outcome:** This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 2 'Living and working in a health-promoting environment'. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards all of the following **expected outcomes**:

- EU and national public authorities regularly use economic and health modelling in policy impact assessments and policy evaluation, and promote the use of these to other stakeholders;
- Stakeholders agree on the most relevant population health and quality of life metrics, including DALYs or QALYs and economic metrics;
- The stakeholder community follows common guidelines and methodologies for integrative socio-economic assessments and cost-benefit analysis of environmental pollution in Europe.

**Scope:** Policy-makers face challenges when devising pollution mitigation measures and having to assess the **health costs emerging from life-long exposures to environmental stressors or the benefits from clean environments**. Deaths and disabilities resulting from pollution carry a quantifiable economic cost to society, but there are significant uncertainties in the cost estimates methodologies. There is also paucity of data to evaluate the economic benefits of

clean environments. Impact Pathway Analysis and Health Impact Assessment (HIA) are methodologies, which can be useful in linking scientific knowledge with environmental economics for informing policy action in diverse sectors such as transport, energy, chemicals, occupational health etc.

Proposed research activities should mainly **aim to improve the calculation of the socioeconomic costs (and/or benefits) of health impacts during the life-course associated to environmental stressors**, or combinations of these, advance methodological approaches and foster their acceptance as common good practice. Proposals should consider all of the following activities:

- Systematic review and exploitation of latest evidence of exposure-response functions and causation ...data from the past 10-20 years
- Identification of data gaps as regards environment and health risk factors and health related tangible and intangible costs and recommendations on priorities for new data collections;
- Advancement of methodological rigor and consistency in accounting for morbidity and mortality, disabilities, linking valuation of statistical life and/or life-years with quality adjustments within a unified framework, based on the most recent data available and adapted to the needs and circumstances in Europe;
- Application of experimental approaches addressing the potential link of quality of life and the burden of disease indicators with more integrative impact indicators and identification of how national contexts can impact on health-related costs of the same environmental and occupational exposure;
- Enhancement of the understanding of the role of discounting and other methods for weighing present and future costs and benefits;
- Development of innovative tools, methods and models, and associated guidelines for health impact assessments and related cost-benefit analysis;
- Consultation of experts and stakeholders on tools, models, methods and assessments developed towards a shared agreement of these;
- Development of case studies involving public authorities comparing the costs of action and non-action in at least three EU or associated countries;
- Delivery of FAIR72 data and a user-friendly access to an open knowledge base including results, methodologies and data appropriate for use in public policies and budget allocations.

Projects could consider the involvement of the European Commission's Joint Research Centre (JRC) in the field of health impacts of environmental stressors.

Neuro	Cardio	Onco	Other
X	X	X	X

## Enhancing cybersecurity of connected medical devices

TOPIC ID: HORIZON-HLTH-2022-IND-13-01

Deadline: **21 April 2022**

Budget: 6mln (20 mln in total, 3 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

**Expected Outcome:** This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:

- Stakeholders (e.g. manufacturers, suppliers, health care providers, integrators, operators) apply measures to identify and address cybersecurity risks and gaps in connected medical devices.
- Stakeholders adopt and use newly developed risk benefit analysis schemes and capabilities for cybersecurity of connected medical devices.
- Stakeholders adopt and use newly developed methodologies and toolboxes for ensuring cybersecurity of connected medical devices by design.
- Stakeholders adopt and use fit for purpose guidance covering challenges posed by connected medical devices, including software.

**Scope:** The proposals are expected to help **strengthening cybersecurity maintaining the performance of medical devices** while preserving or enhancing safety, security and data confidentiality, integrity and availability. The applicants should tackle the cybersecurity issue of connected medical devices and in vitro diagnostic medical devices, in particular those that are connected to the internet, allow remote access to data and exchange private or proprietary data. They should also consider the implications of Regulation (EU) 2017/745211 on medical devices and Regulation (EU) 2017/746212 on in vitro diagnostic medical devices regarding qualification and classification of software. In their proposals, applicants should consider to maximise synergies with relevant initiatives, activities and programmes.

Proposals are expected to address some or all of the following:

- Systematic review of current standards/guidelines/best practices applied to cybersecurity of connected medical devices, with the final objective to identify and specify gaps and requirements based on evidence.
- Propose risk benefit analysis schemes for cybersecurity of connected medical devices, taking into account several novel technological developments (e.g. 5G networks, big data, artificial intelligence, cloud computing, augmented reality, blockchain) and interconnection architectures.
- Explore, develop and validate novel methodologies and toolboxes for ensuring cybersecurity of connected medical devices by design.
- Identify representative case studies, evaluate the applicability of existing guidance MDCG 2019-16 (guidance on cybersecurity for medical devices 213 ) and make recommendations to (better) address specificities of the connected medical device, including software, of different risk classes.
- Assessment of the applicability (and revision) of current guidance, the MDCG 2019-16 (guidance on cybersecurity for medical devices), to connected medical device, including software.

In this topic the integration of the gender dimension (sex and gender analysis) in research and Innovation content is not a mandatory requirement.

Neuro	Cardio	Onco	Other
X	X	X	X

## [Trustworthy artificial intelligence \(AI\) tools to predict the risk of chronic non-communicable diseases and/or their progression \(1\)](#)

[TOPIC ID: HORIZON-HLTH-2022-STAYHLTH-01-04-two-stage](#)

Deadline: **01.02.2022, 2-stage (06.09.2022)**

Budget: 6 mln (60 mln in total, 10 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

**Expected Outcome:** This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 1 “*Staying healthy in a rapidly changing society*”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes.

- Clinicians, medical professionals and citizens have access to and use validated AI tools for disease risk assessment. Hence, citizens are better informed for managing their own health.
- Health care professionals utilise robust, trustworthy and privacy-preserving AI tools that help them to assess and predict the risk for and/or progression ...
- Health care professionals develop evidence-based recommendations and guidelines for the implementation of AI-based personalised prevention strategies. ...
- Health care professionals employ quantitative indicators in order to identify and follow-up on individuals with high risk for the development and/or risk for the progression ...

**Scope:** It is widely recognised that health systems must put more emphasis on prevention and adopt a person-centred approach. Artificial intelligence (AI) along with the increased availability of health data hold great potential to pave the way for personalised prevention and enable progress towards risk prediction and early detection ...This topic will support multidisciplinary research, build on broad stakeholder engagement and support proposals developing novel robust and trustworthy<sup>[1]</sup> AI tools to enable timely personalised prevention approaches for chronic non-communicable diseases/disorders. The topic does not exclude any diseases/disorders.

Proposals are expected to **develop and test AI tools** for assessing and predicting the risk of developing a disease and/or the risk of disease progression once it is diagnosed, taking into account the individuals’ (or groups) genotypes, phenotypes, life-style, occupational/environmental stressors and/or socio-economic and behavioural characteristics, as necessary. Sex and gender aspects should be considered, wherever relevant. The AI tools may include a broad range of technological solutions on their own and/or in combination with other relevant state-of-the-art technologies (i.e. AI algorithms, mobile apps and sensors, robotics, e-health tools, telemedicine etc.) Proposals should implement **proof-of-concept studies** to test and validate the performance of their AI tools in the real-world setting and compare their performance to the established practice.

The applicants should ensure that the AI tools developed are driven by relevant end-users/citizens/health care professionals needs. Therefore, the proposals are expected to introduce concrete measures for the involvement of the end-users throughout the AI development process and not only in the last phases of development. SME(s) participation is encouraged with the aim to strengthen the scientific and technological basis of SME(s) and valorise their innovations for the people’s benefit. **(see next page)**

Neuro	Cardio	Onco	Other
X	X	X	X

## [Trustworthy artificial intelligence \(AI\) tools to predict the risk of chronic non-communicable diseases and/or their progression \(2\)](#)

[TOPIC ID: HORIZON-HLTH-2022-STAYHLTH-01-04-two-stage](#)

Deadline: **01.02.2022, 2-stage (06.09.2022)**

Budget: 6 mln (60 mln in total, 10 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

Proposals should address all of the following:

- Leverage existing high-quality health-relevant **data from multiple sources** (i.e. cohorts, electronic health records and registries, taking into account the individual's genotypic/phenotypic, medical, life-style, socio-economic, behavioural data etc.) and/or generation of new high-quality health data necessary for the rigorous development of the AI disease-risk tools.
- Develop the **adequate performance metrics** to assess the technical robustness of the developed AI tools for risk assessment of disease and/or disease progression and in particular their accuracy, reliability, reproducibility and generalisability. Proposals should assess the possible inherent bias introduced to the AI tools originating from the data quality used for their development.
- Develop the **criteria to assess the effectiveness of the AI tools** for disease risk assessment in terms of improving health outcomes and enabling personalised prevention strategies.
- Implement proof of concept** and/or feasibility studies to validate the AI tools for risk assessment of disease and/or disease progression in a relevant end-users environment and/or real-world setting and assess their performance in comparison to the standard-of-care.

Proposals should adhere to the **FAIR<sup>[2]</sup> data principles** and apply **good practices for GDPR-compliant** personal data protection. Proposals are encouraged to implement international standards and best practices used in the development of AI solutions.

Integration of **ethics and health humanities** perspectives to ensure an ethical approach to the development of AI solutions. In relation to the use and interpretation of data, special attention should be paid to systematically assess for gender and ethnic bias and/or discrimination when developing and using data-driven AI tools.

To **ensure citizens' trust**, wide uptake by user communities and scalability of the solutions across clinical contexts, actions should promote the highest standards of transparency and openness of the AI tool, going well beyond documentation and extending to aspects such as assumptions, architecture, code and underlying data.

Applicants are highly encouraged to deliver a **plan for the regulatory acceptability** of their technologies and to interact at an early stage with the regulatory bodies, whenever relevant.

All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate. These networking and joint activities could, for example, involve the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. This could also involve networking and joint activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Therefore, proposals are expected to include a budget for the attendance to regular joint meetings and may consider to cover the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase. In this regard, the Commission may take on the role of facilitator for networking and exchanges, including with relevant stakeholders, if appropriate.

# Horizon Europe Cluster 1 Health

## Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

[Scaling up multi-party computation, data anonymisation techniques, and synthetic data](#)

[Generation TOPIC ID: HORIZON-HLTH-2022-IND-13-02](#)

Deadline: **21 April 2022**

Budget: 7mIn (30 mln in total, 4 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

**Expected Outcome:** This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The EU contributes strongly to **global standards for health data** through enhancement of common European standards for health data ...
- Innovators have access to advanced secure data processing tools to test and develop robust data-driven digital solutions and services ....
- Cross-border health data hubs further facilitate the innovation process by providing secure, trustable testing environments for innovators.
- Clinicians, patients and individuals use a larger variety of **high quality data tools and services** for wellbeing, prevention, diagnosis, treatment and follow-up of care.
- Researchers and innovators have more opportunities for testing and developing GDPR compliant data driven solutions based on actual needs of the health care environments.

**Scope:** It is essential to speed up and facilitate innovations in the field of data-driven tools and services for wellbeing, prevention, diagnosis, treatment and follow-up of care, among others. However, **limited access by developers to health data and secure testing environments** hinder the development of innovative data-driven digital health products and services. Therefore, the proposals are expected to **scale up multi-party computation, data anonymisation techniques and synthetic data generation**. To ensure privacy, the data analytics should be conducted in a distributed way among processors that grant third parties access to analysis outcomes but not to the underlying data. The developers should have access to distributed testing data sources and cloud and computing resources at large scale, with a view to improving the speed and robustness of multi-party computation solutions for innovators. The aim is to allow secure GDPR-compliant data processing for research, and clinical purposes.

The proposals should consider the **use of synthetic, i.e. artificially generated, data** as they allow researchers and developers to test, verify and fine-tune algorithms in large-scale data experimentations without re-identifiable personal data. (...)

To this end, integration of national/regional health data hubs/repositories/research infrastructures is appropriate to achieve the scope of the topic. The proposals are expected to address all of the following areas:

- Consolidate and scale up multi-party computation and data anonymisation techniques and synthetic data generation to support health technology providers, in particular SMEs.
- Support the development of innovative unbiased AI based and distributed tools, technologies and digital solutions ....
- Advance the state-of-the-art of de-identification techniques, to tackle the challenge of anonymised datasets that can be traced back to individuals.
- Develop innovative anonymisation techniques demonstrating that effective data quality and usefulness can be preserved without compromising privacy.
- Explore and develop further the techniques of creating synthetic data, also dynamically on demand for specific use cases.
- Widen the basis for GDPR-compliant research and innovation on health data.
- Ensure wide uptake and scalability of the methodologies and tools developed ....

# Horizon Europe Cluster 4 Digital, Industry and Space

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

## Horizon Europe Cluster 4 Digital, Industry and Space Bio-materials / biomedical application of materials

Cluster 4 Digital, Industry and Space	total budget (no. of projects) (€ million)	type	deadline	stage
<a href="#">HORIZON-CL4-2022-RESILIENCE-01-13: Smart and multifunctional biomaterials for health innovations (RIA)</a>	19(3)	RIA	30.03.2022	single-stage
<a href="#">HORIZON-CL4-2022-DIGITAL-EMERGING-01-35: Advanced characterisation methodologies to assess and predict the health and environmental risks of nanomaterials (RIA)</a>	17,5(3)	RIA	05.04.2022	single-stage
<a href="#">HORIZON-CL4-2022-DIGITAL-EMERGING-01-19: 2D materials-based devices and systems for biomedical applications (RIA)</a>	6(1)	RIA	16.11.2021	single-stage

More information?



# Horizon Europe Cluster 4 Digital, Industry and Space

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

## Smart and multifunctional biomaterials for health innovations

TOPIC ID: HORIZON-CL4-2022-RESILIENCE-01-13

Deadline: 30 March 2022

Budget: 3-5 mln (17,5 mln in total, 5 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

### ExpectedOutcome:

Multi-functional biomaterials are capable, by virtue of their own material ingredients or surface properties, of achieving several biological responses simultaneously. They may also help to dampen those that are undesirable such as inflammation, infection, corrosion and issues related to bio and immune compatibility, while taking into account the specificities due to sex, race and age.

Projects are expected to contribute to the **following outcomes**:

- Offer solutions through the development of multifunctional biomaterials to address and mitigate multiple bottlenecks in response to unmet clinical needs;
- Provide improved biocompatibility, biospecificity and longevity of medical devices or if relevant, improved bioactivity and/or biodegradability; physiological and biomechanical constraints and implications should also be considered.
- Show that the regulatory and IPR strategies are compatible with the overall research objectives.

### Scope:

Multifunctional biomaterials play a major part in shaping the future of Advanced Therapies and Medical Devices. Health applications may include but are not limited to tissue engineering, artificial organs, implants, bioinks for bioprinting platforms, microfluidics, bioactive scaffolds, wearable and implantable devices, in-vitro diagnostics etc.

Projects funded under this topic should further:

- Develop and/or validate specific multifunctional biomaterials or micro systems for use in an eventual advanced therapy, medicinal product or medical device;
- Preclinical regulatory affairs as well as manufacturing processes would also need to be addressed, including up-scaling and good manufacturing practice (GMP);
- Pay special attention to the needs of Small and Medium-Sized Enterprises (SMEs) as well as to the ultimate clinical applications of these biomaterials;
- Present a solid economical evaluation of possible savings, together with patient benefits.

Proposals submitted under this topic should include a **business case and exploitation strategy**, as outlined in the introduction to this Destination.

This topic is open for international cooperation where the EU has reciprocal benefit, while excluding industrial competitors from countries where the safeguarding of IPRs cannot be guaranteed.

Specific Topic Conditions: Activities are expected to start at **TRL 3 and achieve TRL 5** by the end of the project – see General Annex B.

# Horizon Europe Cluster 4 Digital, Industry and Space

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
			X

## [Advanced characterisation methodologies to assess and predict the health and environmental risks of nanomaterials](#)

[TOPIC ID: HORIZON-CL4-2022-DIGITAL-EMERGING-01-35](#)

Deadline: 5 April 2022

Budget: 2-3 mln (17,5 mln in total, 5 projects)

Type: RIA: Research and Innovation Action

Call text (fragment only):

### Expected Outcome:

The development of reliable and practical tools to ensure the safe and sustainable use of nanomaterials has not kept pace with the rapid commercialization of nanotechnology-enabled products. The dynamic nature of many nanomaterials in complex environmental matrices is recognized as a major challenge for their detection, quantification and characterization. Consequently, there is an urgent need to establish appropriate methods for cost-efficient assessment and prediction of the health and environmental effects of nanomaterials, providing better decision criteria, based on quantitative rather than qualitative information and taking into account the full life cycle of a material. Proposal results are expected to contribute to several of the following expected outcomes:

- Develop high-resolution imaging methods for quantification and characterization of nanomaterials (e.g. nanoplastics) ...
- Increase availability of validated protocols to advance both nanosafety studies and material characterization.
- Ensure appropriate control experiments and more realistic in vitro models to address current gaps in nanotoxicology.
- Deliver reliable data and improved data reporting guidelines, supported by computational modelling, in order to allow the development of grouping and read across methods...
- Develop harmonized standardized test methods that can be used in a regulatory framework including ....
- Increase the efficiency and effectiveness of materials and product development by reducing costs and time for product design, time-to-market and regulatory compliance

### Scope:

- Develop advanced characterization tools and methods for nanomaterials industry to enhance the design and development stages of advanced materials and products contributing to less waste and emissions while improving process quality in line with Life Cycle Assessment framework;
- Develop new in vitro models and tests to assess nanotoxicology;
- Include use cases to validate and demonstrate the approach(es) in industrial settings and involve comprehensive analysis and measurement of process and handling release scenarios and exposure measurements;
- Propose the validated methods to standardization bodies such as ISO or OECD for development of standards, test guidance or a guidance document;
- Demonstrate connectivity with H2020 nanosafety projects and leverage the extensive experience from relevant initiatives. Cooperation with EU funded projects under Industry Commons and other similar initiatives for interoperability and data documentation should be addressed;

In line with the Union's strategy for international cooperation in research and innovation, international cooperation is encouraged.

Specific Topic Conditions: Activities are expected to start at TRL 3 and achieve TRL 5 by the end of the project – see General Annex B.

# Horizon Europe Cluster 4 Digital, Industry and Space

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

## [2D materials-based devices and systems for biomedical applications \(RIA\)](#)

[TOPIC ID: HORIZON-CL4-2022-DIGITAL-EMERGING-02-19](#)

Deadline: **16.11.2021**

Budget: 6 mln (6 mln in total, 1 project)

Type: RIA: Research and Innovation Action

Call text (fragment only):

### **ExpectedOutcome:**

Proposal results are expected to contribute to the following expected outcomes:

New technology solutions exploiting the unique properties of 2D materials (2DM) that would reduce cost and increase the efficacy of diagnostics or therapies, or provide new diagnostics or therapies for which there is currently no solution. It would strengthen Europe's industrial position in, early diagnostics, disease prediction and prevention, disease monitoring and reducing hospitalization time.

### **Scope:**

Proposals should build on the multi-functionality allowed by 2DMs and demonstrate the advantages of combining e.g. biocompatibility, chemical stability, (bio-)sensing and actuating, and integration with flexible electronic technologies, in addition to versatile surface chemistry (for interface with biology) to allow continuous health monitoring and built-in pharmacological interventions.

Emphasis of the proposals should have a translational perspective, addressing how the devices and systems will reach the clinic, preferably led by European industry. Furthermore, the proposals should bring together multidisciplinary teams including engineers, material scientists, pharmacologists, biologists, clinicians, patients, and ethics experts. Potential application areas include: engineering & bioengineering of biochemical or bioelectronic diagnostics or therapeutic devices and platforms; sensors for digital health; electronics for brain-computer interfaces, taking advantage of flexible devices; medical imaging in combination with implantable devices (e.g. MRI); graphene for drug delivery of therapeutics (e.g. for neurological disorders). The safety aspects of the proposed technologies should be given proper consideration.

Proposals should include activities aiming at facilitating future exploitation of results.

Proposals should aim at demonstrating by the end of the project fully functional prototypes operating in relevant environment conditions (TRL 5).

The proposal should also cover the contribution to the governance and overall coordination of the Graphene Flagship initiative.

Specific Topic Conditions: Activities are expected to start at TRL 3-4 and achieve TRL 5 by the end of the project – see General Annex B.

# Horizon Europe Cluster 6 Food, Bioeconomy, Natural Resources, Agriculture and Environment

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

## Examples of health calls

Cluster 6	total budget (no. of projects) (€ million)	type	deadline	stage
<a href="#">HORIZON-CL6-2022-CircBio-02-06-two-stage: Life sciences and their convergence with digital technologies for prospecting, understanding and sustainably using biological resources</a>	12(2)	RIA	15.02.2022	2-stage
<a href="#">HORIZON-CL6-2022-COMMUNITIES-02-02-two-stage: Developing nature-based therapy for health and well-being</a>	19(3)	RIA	ca. 01.02.2022	2-stage

More information?



# Horizon Europe Cluster 6 Food, Bioeconomy, Natural Resources, Agriculture and Environment

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
			X

## [Developing nature-based therapy for health and well-being \(1\)](#)

TOPIC ID: HORIZON-CL6-2022-COMMUNITIES-02-02-two-stage

Deadline: 15.02.2022, 2-stage (06.09.2022)

Budget: 6 mln (19 mln in total, 3 project)

Type: RIA: Research and Innovation Action

Call text (fragment only):

### Expected Outcome:

A successful proposal will contribute to the EU's goal of leading just, digital, economic and ecological transitions that will leave no one behind, supporting in particular European Green Deal priorities such as the biodiversity strategy for 2030. R&I will support the development of **nature-based therapy** to help communities turn the ecological transition into opportunities for good health and well-being, increased resilience, and positive long-term prospects such as the creation of green jobs. Project results are expected to contribute to all following expected outcomes:

- Sharper view of green space management, nature protection, agriculture and forestry sectors as care providers and their linkages with the healthcare, social and educational sectors;
- Stronger evidence base for the causal relationships between nature and health and well-being for more effective nature therapy prescriptions;
- Cost-effective nature therapy prescriptions are more widely used in the health care sector;
- Greater citizen and policy-maker awareness of the positive benefits of nature for health and well-being;
- Wider utilization by healthcare professionals and citizens of nature therapy as a form of preventive medicine.

### Scope:

Nature affects human health in different ways. In particular, urban environments can have a negative impact on physical and mental health. This is due to urban stressors such as increased noise levels, higher crime rates and higher levels of pollution. The total global burden of disease attributable to mental illness has recently been estimated to be as high as 32% of total years lived with disability and 13% of disability-adjusted life-years, on par with cardiovascular and circulatory diseases. **It is important, therefore, to determine the degree to which nature experience might lessen and address this burden.** Even more so in view of the fact that the opportunities and time spent in nature are decreasing.

However, despite many putative positive correlations identified between nature and health and well-being, the causal understanding of relationships between health and nature exposure are not well understood. The long-term effects are also less well studied and recognised in policies. Social, economic and cultural factors strongly mediate the strength and direction of linkages between health and nature. Age, gender and especially socio-economic status may modify the association between greenness and health behaviours and outcomes and need to be better understood to create more effective nature therapy. Additionally, mental health benefits may vary with the type of interaction with nature and the form of sensory input. Furthermore, the health and well-being benefits of exposure to nature are affected by cultural perspectives and experiences relating to social interaction and contact with the natural environment. (see next page)

# Horizon Europe Cluster 6 Food, Bioeconomy, Natural Resources, Agriculture and Environment

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
			X

## [Developing nature-based therapy for health and well-being \(2\)](#)

TOPIC ID: [HORIZON-CL6-2022-COMMUNITIES-02-02-two-stage](#)

Deadline: **15.02.2022, 2-stage (06.09.2022)**

Budget: 6 mln (19 mln in total, 3 project)

Type: RIA: Research and Innovation Action

Call text (fragment only):

**A successful proposal should:**

- Develop a common framework to increasingly recognise and **promote contact with nature, including protected areas and other green and blue spaces**, as a cost-effective response for the prevention and treatment of human health and well-being;
- Propose an interdisciplinary and cross-sectoral approach, including the involvement of the health care sector, land owners, green space management and nature protection sectors;
- Improve schemes **monitoring nature-health linkages** to enhance the evidence base and tools for the health care sector, green space management, nature protection, urban planning and landscape architecture;
- Develop **longitudinal prospective methods, (quasi-) experiments** or well-controlled interventions, to provide more evidence of the causal relationships between nature and health and well-being:

Understanding of when people explicitly choose to go to an urban green space and what experiences they have there (e.g., active versus passive activities).

Determining the type of interactions and dose of interactions necessary for long-term health and well-being benefits.

Understanding the mediators of the health-nature relationship, such as age, gender, socio-economic status or culture.

Considering the difference between greenness quantity and quality and determining which aspects of natural features are relevant to mental health.

Understanding how different geographical locations and factors such as population density affect the health-nature relationships;

- Test **nature therapy sessions**, identify best-practices and develop the necessary tools and guidelines for integration of nature-based care in the public health sector;
- Identify **legal and administrative arrangements**, partnerships, and financial mechanisms for implementation of nature therapy sessions.

The proposals should address **all of the above points**. Proposals should bring together from the start multiple types of scientific expertise in both health and natural sciences, as well as social sciences and humanities, together with a variety of community and health sector representatives, businesses, civil society organisations and citizens.

Proposals should ensure that all evidence, information and project outputs will be accessible through the Oppla portal (the EU repository for nature-based solutions)[1].

.....

Social innovation is recommended when the solution is at the socio-technical interface and requires social change, new social practices, social ownership or market uptake.

In order to achieve the expected outcomes, international cooperation is strongly encouraged, **in particular with the USA, Japan and the LAC region**.

# EIC Work Programme 2022



**EIC Pathfinder**

Support to research teams to research or develop an emerging breakthrough technology

## Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x	x	x	x

**Deadline:** 26.10.2022

**Budget:** ca. 4mIn/project (5 projects per topic)

### Cardiogenomics:

- To identify gene variants of high biological significance or other key molecules associated with the CVDs that could guide the physician in their clinical management and monitoring of these CVDs;
- To identify novel targets based on these variants for specific CVD indication(s) that would allow for the development of first in class therapies for the same indication;
- To seek for novel technological solutions that could contribute to the development and acceleration of first in class therapies for the above indications

### Healthcare Continuum technologies

- Develop a novel device/s or system for unobtrusive proactive healthcare. The targeted technology should offer life-long health status monitoring and elements of predictive medicine with methodologies grounded in existing scientific evidence.
- The end objective must be a Proof-of-Concept and evidence of safety and efficacy, with particular attention to minimising false positives that could hamper its real-world use.
- The targeted technology should offer a clinically acceptable solution amenable to successful evaluation under common Health Technology Assessment (HTA) methodologies.
- The path to future integration in the European healthcare workflow, specifically in relation to the inter-operability with existing infrastructures, as well as take up and compliance by appropriate patient populations, should be plausible.

**Would you like more information on these topics?**





# HFSP Research Grant Program - HFSP

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X	X	X	X

**Purpose:** Human Frontier Science Program (HFSP) Research Grants support **innovative basic research** into fundamental biological problems with emphasis placed on **novel and interdisciplinary approaches** that involve scientific exchanges across national and disciplinary boundaries (see [guidelines](#)). Participation of scientists from disciplines outside the traditional life sciences such as biophysics, chemistry, computational biology, computer science, engineering, mathematics, nanoscience or physics is recommended because such collaborations have open up new approaches for understanding the complex structures and regulatory networks that characterize living organisms, their evolution and interactions.

**Who can apply:** Research grants are provided for teams of scientists from **different countries** who wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. They should **not** have collaborated before and should propose a project **significantly different** from their ongoing research. Preliminary results are not required and applicants are expected to develop new lines of research through the research collaboration. It is understood that such research inherently contains risks and HFSP expects that teams of applicants address the risks and outline mitigation strategies for their research in case of failure and how they intend to achieve their goals. Applications for applied research, including medical research typically funded by national medical research bodies, will be deemed ineligible (see [guidelines](#)).

**Two types of Grant are available:** Research Grants – Early Career (all members within 5 years of obtaining an independent position) and Research Grants – Program.

**Budget:** \$265,000 for a team of 2; \$365,000 for a team of 3; \$465,000 for a team of 4 or more.

**Deadlines: Step 1 :** Letters of Intent: i. Compulsory initiation of a letter of Intent by obtaining a LIXXXX/2022 reference number by **March 24th 2022**; ii. Submission of Letters of Intent: **March 31th 2021**.

**More information** [HERE](#) and [HERE](#)





# Programma Onderzoek & Implementatie and Exploratie - KWF

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
		x	



shutterstock.com • 453162688

## VERWACHTE CALLS (wijzigingen voorbehouden)

### Call 2022-3 / Ontwikkeling en Implementatie

Opening call: medio/eind januari 2022  
Sluiting call: eind maart 2022

[Meer informatie:](#)  
[Downloads Programma](#)  
[Onderzoek & Implementatie](#)

### Call 2022-4 / Exploratie

Opening call: februari 2022  
Sluiting call: eind april / begin mei 2022

### Vier aandachtsgebieden (voor calls 2022-1 en 2022-2, wijzigingen voor calls 2022-3 en 2022-4 voorbehouden)

Binnen deze speerpunten hebben wij een aantal specifieke mogelijkheden en/of onvervulde behoeften geïdentificeerd. Deze aandachtsgebieden lichten we graag uit in de calls **2022-1** (Ontwikkeling en Implementatie) en **2022-2** (Exploratie) om een extra stimulans te geven aan deze onderwerpen en ze in een stroomversnelling te brengen:

- [1. Bewijsvoering carcinogene werking van omgevingsfactoren](#)
- [2. Technieken die diagnostiek verschuiven naar perifere zorg](#)
- [3. Evidence based symptoombestrijding in de palliatieve zorg](#)
- [4. Klinische onderzoeken gericht op de doorontwikkeling van geneesmiddelen en behandelingen in oncologische indicaties met een kleine patiëntengroep](#)



# Alzheimer Nederland Call Biomedical Research

Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
x			

Alzheimer Nederland richt zich met deze call op innovatief, kennis genererend, mechanistisch onderzoek. Binnen deze ronde wordt fundamenteel, translationeel, en klinisch onderzoek gefinancierd dat zich richt op het ontrafelen van oorzaken en onderliggende mechanismen om binnen een afzienbare periode een concrete lijst met aangrijpingspunten te hebben waarvoor behandeling ontwikkeld kan worden.

In dat kader biedt Alzheimer Nederland vier soorten grants aan:

- pilot grants, maximaal 50.000 euro
- standard grants, maximaal 150.000 euro
- major grants, maximaal 300.000 euro
- Dutch-French en Dutch-German Cross-Border grants

Richtlijnen: Toegekende fondsen mag men uitsluitend voor onderzoek gebruiken. Wij financieren geen overheadkosten van instituten, aanschaf van kapitaalintensieve apparatuur of aanbouw van gebouwen. Alzheimer Nederland verleent beurzen aan meer dan één onderzoeker van dezelfde groep, mits de ingediende projecten elkaar in wetenschappelijk opzicht niet overlappen. Bekijk de "[Alzheimer Nederland Funding Guidelines 2022](#)".

**Aanvragen:** Het aanvraagproces verloopt digitaal via ons online aanvraag portaal en is opgesplitst in 2 fasen. De sluitingstermijn voor het inzenden van de **LoI is 1 februari 2022, vóór 13.00 uur**. Pilot grants mogen worden aangevraagd door jonge post-docs die uiterlijk 31 december 2022 promoveren.

**Meer informatie:** [HERE](#)





### Suitable for which pillars of DHI?

Neuro	Cardio	Onco	Other
X			X

De Stichting tot Steun VCVGZ hanteert bij het toekennen van subsidie strikte criteria. Voor het wetenschappelijk onderzoek en voor de innovatieve projecten gelden verschillende eisen.

## STICHTING TOT STEUN VCVGZ

### OVER VCVGZ

De Stichting tot Steun VCVGZ kent subsidiegelden toe voor wetenschappelijk onderzoek of innovatieve projecten in de psychiatrie. Zij doet dat vanuit een breed christelijk perspectief.

### PROJECTEN

De Stichting tot Steun VCVGZ financiert zowel wetenschappelijk onderzoek als innovatieve projecten in de geestelijke gezondheidszorg.

### SUBSIDIE

De Stichting tot Steun VCVGZ hanteert bij het toekennen van subsidie strikte criteria. Voor het wetenschappelijk onderzoek en voor de innovatieve projecten gelden verschillende eisen.

### RIJKE HISTORIE

De Vereniging tot Christelijke Verzorging van Krankzinnigen en Zenuwlijders is in 1884 opgericht door Lucas Lindeboom met als doel christelijke verzorging te bieden aan psychiatrische patiënten.

**What?** De [Stichting tot Steun VCVGZ](#) financiert wetenschappelijk onderzoek en innovatieve projecten in de geestelijke gezondheidszorg, waarvoor in de reguliere onderzoeks- en instellingsfinanciering onvoldoende ruimte is.

**For who?** Zowel GGZ-instellingen als wetenschappelijke instituten kunnen aanvragen indienen voor financiering van projecten.

**When?** 15 November 2021, 11 April 2022, 19 September 2022  
**How much?** tbd  
**More information?** [HRE](#) en voorbeelden van gehonoreerde projecten [HERE](#)

